Shots:

• BPOM has approved Qdenga for the prevention of dengue disease caused by any serotype in patients aged 6 to 45yrs. The therapy is expected to be available in the coming months
• The approval was based on an ongoing P-III (TIDES) trial to evaluate Qdenga in ~20000 healthy children & adolescents aged 4 to 16yrs. with dengue endemic across Asia & Latin America. The results showed continued overall protection against dengue illness & hospitalization @3yrs. after vaccination regardless of prior dengue exposure, was well tolerated with no safety risks
• Qdenga is currently under regulatory review for the prevention of dengue in children and adults in the EU and dengue-endemic countries outside the EU

Ref: Businesswire | Image: Takeda